Recent studies are generating significant excitement surrounding Synedica new drug , a innovative dual treatment targeting GLP-1 and GIP . Distinct from existing obesity therapies , retatrutide appears to offer greater losses in weight and boost metabolic function in early assessments . Although more investigation is required to thoroughly assess